Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: J Neurochem. 2011 Oct 3;119(4):868–878. doi: 10.1111/j.1471-4159.2011.07470.x

Figure 6.

Figure 6

Smad3 knockdown inhibits the amount of TGF-β induced 4-sulfation in astrocytes. Representative western blot showing 2H6 (a), CS56 (b) expression in conditioned media harvested from astrocytes treated with TGF-β (10ng/ml) for 3 days in the presence of LV-ShSmad2 or LV-ShSmad3. Quantification of westerns for (b) 2H6 and (d) CS56 immunoreactivity (mean ± s.e.m., n=3–4). Data are presented as percentage of expression in TGF-β treated vs untreated samples and compared to the LV-Sh Control. (*p<0.05; ANOVA with bonferroni post test).